Artelo Biosciences shares are trading higher after the company announced a Definitive Investigator-Initiated Study Agreement with the Belfast Health and Social Care Trust, to be funded by Glaucoma UK and the HSC R&D Division. The study will evaluate the effects of Artelo's peripherally selective synthetic cannabinoid, ART27.13, in patients with glaucoma or ocular hypertension.